J Cancer 2016; 7(12):1599-1604. doi:10.7150/jca.16208 This issue


Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers

Jung Hoon Kim, Bum Jun Kim, Hyeong Su Kim, Jung Han Kim

Division of Hemato-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Chuncheon, South Korea.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Kim JH, Kim BJ, Kim HS, Kim JH. Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers. J Cancer 2016; 7(12):1599-1604. doi:10.7150/jca.16208. Available from https://www.jcancer.org/v07p1599.htm

File import instruction


Cancer immunotherapy is at dawn of the Renaissance after the Medieval Dark Ages. Recent advances of understanding tumor immunology and molecular drug development are leading us to the epoch of cancer immunotherapy. Some types of immunotherapy have shown to provide survival benefit for patients with solid tumors such as malignant melanoma, renal cell carcinoma, or non-small cell lung cancer. Several studies have suggested that immune checkpoint inhibition might be effective in some patients with gastrointestinal cancers. However, the era of cancer immunotherapy in gastrointestinal cancers is still in an inchoate stage. Here we briefly review the current status and perspective of immunotherapeutic approaches in patients with gastrointestinal cancers.

Keywords: Gastrointestinal cancers, Immunotherapy, Cancer vaccines, Immune checkpoint inhibitors, Review.